Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Just over half of MS patients get DMD therapy

Key clinical point: DMD treatment in this commercial population was low.

Major finding: Among MS patients followed for 2 years, 43% had no claim for a DMD.

Study details: A retrospective administrative claims study of 63,946 patients with MS.

Disclosures: Funding for the study was provided by EMD Serono, a Merck company. Dr. Phillips is an employee of the company.


Phillips A et al. ACTRIMS FORUM 2019, Abstract 001.